About: Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 08 August 2013

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) наукова стаття, опублікована в серпні 2013 (uk) artículu científicu espublizáu n'agostu de 2013 (ast) مقالة علمية نشرت في 08 أغسطس 2013 (ar) scientific article published on 08 August 2013 (en)
publication date	wds:Q37091366-282E38E9-3B11-469C-8C85-9DFBE1662AF5
publication date	2013-08-08 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37091366-BAFA8CAF-5453-4E8E-8918-971B75F75130
language of work or name	English
cites work	wds:Q37091366-0FAEA3B4-A5C1-4391-9B26-855C335449F4 wds:Q37091366-12ABEF32-A011-40B5-A3E2-81246CAA85EC wds:Q37091366-17708B0C-5E4B-40C3-9F82-7FD2B48D8C5D wds:Q37091366-3003297D-9C08-4D82-B14E-60361AFB4B01 wds:Q37091366-3966EB01-1CF0-49FE-AF1A-7D044A6B4A0E wds:Q37091366-4FDDAA38-877B-4870-B3D5-0AEFA5F1F59A wds:Q37091366-5286E7F6-1B08-4DA8-8532-C1564140B8F1 wds:Q37091366-5AEE140A-F652-4852-9C52-8C1311C65C8A wds:Q37091366-5E2ED8D9-590B-42C2-883F-B5A84C635190 wds:Q37091366-5E300876-B43F-41F6-AD27-270F49A6737C wds:Q37091366-653E8658-8A51-46D9-889F-33DB9C17406D wds:Q37091366-6F2DF9E2-B4C2-4130-B74A-492C8DE06225 wds:Q37091366-75E7BFAD-0DCF-47FD-9BF8-31B653B9232F wds:Q37091366-80EAE2D9-7693-496F-BA77-F568A392C436 wds:Q37091366-9AF3FC94-4C39-4EE1-8B92-18E480E19132 wds:Q37091366-9C7D10E0-124F-49E8-890E-4A22E08A01A4 wds:Q37091366-A931A9C7-7F9E-49F8-ADD3-C13883BFC717 wds:Q37091366-AD71C8BB-5B86-43E8-897A-17764068E597 wds:Q37091366-B4C6D682-3433-4937-B34E-3A4D320FE020 wds:Q37091366-C3A4D1B6-F215-40E7-82B6-5E179394D458 wds:Q37091366-CBBF319B-F16F-48C6-9156-832DA8C40C95 wds:Q37091366-D23594B2-0C87-4348-AFA3-1B407CC24A91 wds:Q37091366-D3FB5E19-45C8-4B47-ABCA-AA929C701265 wds:Q37091366-DBC75A97-104A-4CD7-8BD9-F7BF9CC15A4F wds:Q37091366-DC50E1B8-8CC0-4C9F-9E82-226462F5C6CE wds:Q37091366-DD18ED23-FB09-4813-9A3F-26EC33E2057F wds:Q37091366-DDE209B4-B85E-4D50-A82E-7E63BAB388C8 wds:Q37091366-E4D71086-4E6C-490B-8860-A3A69B688B0A wds:Q37091366-ECBB1BA1-DC25-47A9-A99B-9D526B029C1F wds:Q37091366-F1D51C97-A998-48E0-801A-CB3D28DE34F5
cites work	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Chemotherapy-Induced Nausea and Vomiting Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Antiemetics: American Society of Clinical Oncology clinical practice guideline update Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Why Do We Need Another Antiemetic? Just Ask Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale Prevention of cisplatin-induced delayed emesis: still unsatisfactory. Italian Group for Antiemetic Research Initial control of chemotherapy-induced nausea and vomiting in patient quality of life A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis
author name string	wds:Q37091366-8DBA914D-0DCD-4730-A95D-FD4A27FAA673 wds:Q37091366-903D64D5-D83B-42B3-BAD3-2C8CD8660CED wds:Q37091366-BA036AEF-7152-423A-AF64-2D213D87E0EA
author name string	Alison Jones James Pellissier Samantha Humphreys
rdfs:label	Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK (en) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. (nl)
skos:prefLabel	Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK (en) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. (nl)
name	Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK (en) Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. (nl)
title	wds:Q37091366-63A322D3-CF2A-4835-BB75-55A05D3BE72C
title	Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK (en)
page(s)	wds:Q37091366-7342740A-3E6D-4357-A3C4-CD5A49A0DD3A
page(s)	215-224
instance of	wds:Q37091366-87EBD2D4-8FFF-4FC9-AA34-B63DC2B5FFFB
instance of	scholarly article
main subject	wds:Q37091366-C13C843D-BFE3-4E69-919B-4B8BBE3F8254

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 195 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software